Introduction
============

In the 2010 update to its 2004-2009 *Strategic Plan* [@B1], NIH\'s Office of Dietary Supplements (ODS) encourages research assessing the effects of dietary supplements on biomarkers associated with chronic diseases, optimal health and improved performance. One major biomarker of ODS\'s goal was addressed in the *Surgeon General\'s Report on Bone Health*[@B2] estimating that by 2020 half of all American citizens over 50 will be at risk of fractures due to poor bone health. The SG concluded that there is a bone health crisis in America due to increasingly sedentary lifestyles, absence of current information about bone health, and inadequate nutrition. The SG recommended that people of all ages take steps to improve their bone density (BMD) by ensuring that they are getting the recommended amounts of calcium and vitamin D~3~, and that supplementation may be helpful in meeting these nutritional goals. Based on findings in the *Surgeon General\'s Report on Bone Health,* a "call to action" was issued for the development of bone health plans that incorporate three components: (1) increased physical activity (2) improved health literacy, and (3) improved nutrition.

In spite of the SG\'s "call to action", calcium deficiencies remain prevalent throughout the world [@B3] as well as in the US [@B4]. In addition to the persistence of sedentary lifestyles, poor nutritional habits, and lack of health literacy, there are other challenges to America\'s bone health that could benefit from supplementation. The increasing number of the elderly is extending the progressive age-related decline in BMD, thereby increasing the need for additional supplemental calcium and vitamin D~3~ [@B5]. There are concerns that current farming techniques are depleting the nutritional composition of vitamins and minerals in our food supply [@B6]-[@B8]**.** A wide number of diseases and medications have been found to have concomitant adverse effects on bone health [@B9]-[@B13] including the increasing use of SSRIs for the treatment of depression [@B14]-[@B17] and contraceptives [@B18]. Since intentional and unintentional weight loss typically depletes bone density [@B19]-[@B30] Americans obsession with dieting will increase the need for supplementation. This is also true for the ten-fold increase in the number of bariatric surgeries performed in the U.S. to combat the adverse effects on bone health found associated with these surgeries [@B31],[@B32]. In addition to the decline in bone health associated with sedentary lifestyles, excessive physical activity observed in athletes, particularly young athletes, has been shown to have adverse effects on bone health, which could be improved with supplementation [@B33]-[@B34]. These factors suggest that the SG\'s 2004 call to action to develop safe and effective bone health plans is as relevant today as it was six years ago, and there is an extensive body of evidence suggesting supplementation with calcium and vitamin D~3~ could help reverse what the SG concludes is a crisis in bone health.

Much of the evidence supporting the value of calcium supplementation is summarized in an exhaustive meta-analysis [@B5] of randomized trials involving 63,897 subjects 50 years of age and older, most of whom were healthy postmenopausal women with an average age of 67.8 years. The meta-analysis includes 23 trials of 41,419 subjects in which changes in BMD were the outcome measure, or one of the outcome measures. No studies reported that supplementation worsened age-related declines in BMD. Nor were there any studies suggesting that supplementation increased BMD over the study period. The overall finding was that with or without vitamin D~3~, calcium supplementation was associated with a "reduced rate of bone loss".

In view of these findings, studying another "me too" or "more of the same" product that also simply slows BMD loss would not help to solve the bone health crisis. What seemed more promising was a bone health plan with potential to halt, or even reverse, age-related BMD loss- a goal made possible with the Comparative Effective Research (CER) model. As The American College of Physicians defines it, CER studies evaluate the relative clinical effectiveness, safety, and cost of two or more medical services, drugs, devices, therapies, or procedures used to treat the same condition [@B35]. Without demonstrating the superiority over the existing standard of care and competing interventions, the acceptability of an intervention becomes heavily dependent upon a company\'s marketing capability, as opposed to product superiority proven with safety and efficacy test results [@B36]. The emphasis of CER studies is to demonstrate the superiority of existing products and standards of care [@B37]. These types of studies span available interventions from pharmaceutical treatment, to lifestyle modifications such as diet, physical activity, and complementary and alternative therapies that are often initiated without physician input. But CER studies face publication challenges that need a paradigm shift in the scientific community to gain acceptance when competing against studies using placebo or control group protocols [@B38]-[@B41].

The purpose of this research was to conduct a CER study comparing changes in baseline BMD in healthy women over 40 years of age who followed one of the three different bone health Plans shown in **Table [1](#T1){ref-type="table"}**.

Comparisons were also made with two references groups of the same age and gender that were used to calculate expected changes, one without any form of intervention, and the other using changes reported in studies using a variety of non-plant sources of calcium.

Materials and Methods
=====================

The protocol for Plans 2 and 3 were approved by the RCRC Institutional Review Board ([www.RCRCIRB.com](http://www.RCRCIRB.com)), Austin, TX, Protocol number 1252006. The protocol for Plan 1 was approved by the researcher\'s ethics committee. Considerable effort was expended to recruit and enroll subjects using the same enrollment procedures in order to facilitate between-group comparisons on relevant outcome measures.

Due to budget restrictions, instead of simultaneously enrolling a control group, the study sponsor chose to compare the three treatment groups effects with a pre-existing annualized expected change in BMD for women over 40 years of age, derived from data showing that after midlife there is an age-related yearly loss in both sexes of 1% [@B42] and an accelerated loss of up to 2% for 14 years for women of menopausal age [@B43]. Additional data were obtained from norms provided by the DXA equipment manufacturer (GE Lunar), the researcher\'s database of over 26,000 total body measurements, and from the National Osteoporosis Foundation [@B44]. Based on these sources, we estimated a non-treatment effect of 0.75% per year. This may be a somewhat conservative estimate in view of population-based longitudinal studies suggesting that, starting at age 40, there is minor, but significant, annual bone loss [@B45] that increases to 0.5% to 0.9% a year in perimenopausal women [@B46]-[@B49], to above 1% after menopause [@B48],[@B49] after which the decline remains about 1% [@B45],[@B50],[@B51]. Other studies suggest after midlife there is an age-related yearly loss of bone in both sexes of 1% [@B52] which is accelerated to 2% for up to 14 years in women around the age of menopause [@B53]. In men, a small loss is detected in 40-year olds [@B45] that increases to a \~0.8% per year into old age [@B45],[@B50]-[@B52]. More recently, another review has suggested that women will lose 35% to 39%, men 17%-19%, of lifetime bone loss after achieving peak bone mass at ages 30-40 years [@B54], changes that are consistent with the previously cited studies.

Another comparison was also made between the 3 active treatment groups with a -0.1% expected annualized changes in BMD when taking vitamin D~3~ and non-plant sources of calcium. This calculation was made from studies cited in Tang et al.\'s [@B5] exhaustive review and additional data provided in studies [@B55]-[@B59] not cited in Tang et al.\'s review. The general conclusion from these studies is that supplementation with calcium and vitamin D can slow age-related declines in BMD, but none of these studies suggested that supplementation can increase BMD levels.

**Improved nutrition.**The bone-health supplements in these plans were analyzed by Exova Labs, Chicago, IL for confirmation of nutrient levels and absence of heavy minerals and other contaminating ingredients. Calcium, magnesium and other minerals were validated by Advanced Labs, Salt Lake City, UT.

The supplement provided to all study groups contained a plant-sourced form of calcium with a research identity of DN0361 (commercially known as \'AlgaeCal\' or \'AC\') made by milling whole, live-harvested sea algae found on the South American coastline. In addition to calcium, the algae contained other naturally occurring minerals in the following rank-order of percentage: carbon, chloride, magnesium, manganese, selenium, silicon, sodium, strontium, titanium and vanadium, boron, silica, and copper. Many of these minerals have been reported to play a role in bone health. A recent in-vitro study [@B60] demonstrated superiority over the two most commonly used calcium salts: calcium carbonate and calcium citrate. Cultured human osteoblast cells (hFOB 1.19) were treated with AC, calcium carbonate or calcium citrate. Alkaline phosphatase activity was significantly increased with AC treatment when compared to control, calcium carbonate or calcium citrate (4.0, 2.0 and 2.5-fold, respectively). Proliferating cell nuclear antigen expression (immunocytochemical analysis), DNA synthesis (4.0, 3.0 and 4.0 fold, respectively) and Ca2+ deposition (2.0, 1.0 and 4.0 fold, respectively) were significantly increased in AC treated cells when compared with control, calcium carbonate, or calcium citrate treatment. AC treatment significantly reduced oxidative stress when compared to calcium carbonate or calcium citrate (1.5, 1.4 fold, respectively). This earlier study demonstrated that AC exhibited unique properties compared to calcium carbonate or calcium citrate on a cellular level, which suggests the need for human intervention studies such as the present study. Furthermore, safety and toxicological investigations were conducted using AC and demonstrated its broad spectrum safety [@B61].

**Health literacy.** To provide a health literacy component, with permission from the author, subjects following Plans 1 and 2 were provided with reprints from Chapters 5, 8, 9 &10 of a published book dealing with changes in body composition [@B62]. These chapters provided information on bone density and on the pedometer-based physical activity program. Calorie estimation charts and glycemic load tables of over 300 common foods designed to increase the quality of carbohydrate intakes were also included [@B62]. Additional health awareness was gained from the consistent stream of feedback from the pedometer-based program described below.

**Physical Activity**. To increase physical activity levels, subjects were asked to wear a pedometer during their waking hours and to record and track their daily activity levels using the charts and graphs provided in their health literacy booklet. They were also asked to follow the instructions for personalizing the pedometer program to their personal goal weight. The Digi-Walker pedometer (HealthTech Products, LLC, San Antonio, TX) used in this study is considered among the most reliable and valid of pedometers available [@B63],[@B64].

**Subjects.** For all three plans, subjects were contacted using the investigators\' DXA (Total Body Dual-energy X-ray Absorptiometry) database, from participants at a local health fair, and from referrals from subjects who agreed to participate. All subjects certified that they had reviewed the Informed Consent with their personal healthcare provider or physician and that they had no medical conditions that would preclude their participation. However, pregnant and lactating women were excluded irrespective of this certification. Subjects were asked to refrain from taking other bone-health supplements during the study. In all three treatment groups, subjects and research technicians were blinded with regard to the subjects\' baseline test results. For Plan 1, 60 adults completed a baseline DXA test, 58 agreed to participate for the one-year study period and 35 ultimately completed the study per-protocol (PP). For Plan 2, a total of 274 S\'s were invited to complete a bone density test and to have the study components explained to them prior to enrolling for the study. Of these, 158 agreed to participate, 125 of whom ultimately completed the study PP. For Plan 3, 80 adults were invited to complete a bone density test and to have study components explained to them prior to enrolling, 58 of whom agreed to participate and 51 completed the study PP. **Figure [1](#F1){ref-type="fig"}** shows a flow diagram through the study for the three study groups.

To encourage candid reporting to allow for dose-related and compliance comparisons, all enrolled subjects were paid a "reporting fee" of \$2.00/day for providing daily reports of their supplement usage and side effects. Throughout the study, subjects were repeatedly reminded that this fee was not an incentive for taking the product, but rather was for the purpose of encouraging candid reporting to allow for analyses of the effects of adherence. Subjects were also advised that the reporting fees would be paid irrespective of product usage as long as the participant completed all ending tests. This procedure was also designed to provide an additional measure of product efficacy on the assumption that if a plan was efficacious, compliant subjects should outperform partially compliant subjects.

**Outcome Measure of efficacy.**Although the primary outcome measure for all three study groups was changes in BMD among highly compliant subjects when following each of the three plans, data was also reported for the entire cohort for each Plan. BMD was assessed by dual-energy X-ray absorptiometry (DXA) total body scans (GE Lunar, LUNAR Corporation, Madison, WI, USA). Longitudinal precision of the DXA unit was monitored using repeated measures of total bone density phantoms provided by the manufacturer.

**Outcome Measure of safety.**To assess safety in all three Plans at baseline and at the end of the study period, subjects completed the 50-item Quality of Life inventory [@B64] shown in **Table [2](#T2){ref-type="table"}**, the 43-item blood chemistry panel shown in **Table [3](#T3){ref-type="table"}**, and daily tracking self-reports on positive/negative reactions to the product and product usage.

**Compliance.**In order to obtain a compliance rating (since poor compliance is a major obstacle to obtaining the full benefit of bone-health supplements) [@B5], the research technician who had the most frequent contact with S\'s (subjects) rated the subjects\' compliance with the protocol using a 5-point scale. Each group was then rank-ordered and dichotomized at the median. When making these ratings and classifications, both the technician and the investigator were blinded with respect to the subject\'s BMD measurements. Those above the median were classified as "compliant", and those below the median were classified as "partially compliant."

Statistical Methods
-------------------

Since the study period for Plan 1 was one year and the study period was six-months for Plans 2 and 3, BMD changes and comparisons were reported as mean annualized percent change (MPAC). Annualizing changes also allowed easier comparisons with other studies reported in the literature.. Continuously distributed data were summarized with the mean and standard deviation; binary outcomes were summarized with counts and percents. Study groups were contrasted on MAPC (Mean Annualized Percent Change in BMD) with analyses of covariance with adjustment for age and sex. Group contrasts with regard to binary outcomes were made with Pearson\'s chi-square. All statistical testing was 2-sided with a significance level of 5%. SAS Version 9.1.3 for Windows (SAS Institute, Cary, North Carolina) was used throughout.

Results
=======

**All subjects**. As shown in the baseline characteristics in **Table [4](#T4){ref-type="table"}**, with the exception of the higher level of body fat in subjects following Plan 1 vs. Plan 2, there were no significant differences between the three groups in baseline BMD or in the 4 variables related to BMD, thus suggesting that the treatment groups were statistically similar in spite of the sequential enrollment of subjects. There also were no differences on these baseline demographics between subjects who chose not to enroll and those who completed PP, or between those who enrolled, but dropped out, as compared to those who completed PP. Subjects in all three plans had an increase in MAPC: Plan 1=1.20%, Plan 2=0.33%, and Plan 3=2.5%. Using a repeated measures t-test, MAPC in Plan 1 and 3 were significant (P=0.027 and P=0.002 respectively), but the MAPC in Plan 2 failed to reach significance (P=0.430). However, the MAPC in all three Plans was significant when compared to the expected-change non-intervention normative group (P\<0.001) and the reference group derived from a literature review (P\<0.001, P=0.026, and P\<0.001 respectively.)

**Compliant sub-groups**. As shown in the baseline characteristics in **Table [5](#T5){ref-type="table"}**, with the exception of the higher BMD in Plan 3 as compared to Plan 1 (P=0.025), and the higher scale weight in Plan 2 versus Plan 3, there were no significant differences between the baseline demographics for the three groups, suggesting that they were reasonably similar at baseline. Among the compliant sub-group, there also was no significant differences on these baseline demographics between subjects who chose not to enroll and those who completed PP, or between those who enrolled, but dropped, as compared to those who completed PP.

As shown in **Figure [2](#F2){ref-type="fig"},** subjects following all three plans had an increase in MAPC: Plan 1=1.30%, Plan 2=2.00%, and Plan 3=4.1%. Using a repeated-measures t-test, the MAPC from baseline in all three Plans was significant (*P*=0.003, *P*=\<0.001, and *P*=0.003, respectively). The MAPC in Plan 3 was significantly greater than Plan 1 (*P*=0.002), but was not significantly greater than Plan 2 (*P*=0.262) nor was the difference between Plan 1 and Plan 2 (*P*=0.063). Although not shown in **Figure [2](#F2){ref-type="fig"}**since we had no compliance data on the two expected change groups, comparisons between the three Plans and all subjects in both expected change groups revealed that the MAPC in all three Plans was significantly greater (*P*\<0.001) than both of these groups.

With regard to the QOL shown previously in **Table [2](#T2){ref-type="table"}**, there were no significant baseline/ending changes in any of the 50 items or in a total QOL score (the sum of all 50 items). Assessment of safety using the QOL is straight-forward. An increase in the total scale or individual item scores suggests increased risk and potential adverse effects. Similarly, evaluation of changes in cholesterol, LDL, Triglycerides, HDL/Total ratio, glucose, and C-reactive protein; and decreases in HDL suggest a negative outcome and potential adverse reaction. In all three Plans, there were no statistically significant changes in any of these "uni-directional" test scores. However, evaluating changes in the remaining 37 chemistries is less straight forward since they are "multi-directional" where both increases or decreases could be associated with either positive or negative outcomes. Additionally, with the remaining 37 chemistries, it is probable that some changes could be statistical artifacts. Therefore, instead of using changes from baseline in all 37 chemistries, we compared the number of changes in scores that were in the normal or acceptable ranges at baseline with those that became abnormal or unacceptable by the end of the study. In all three groups and sub-groups, none of the normal scores were abnormal by the end of the study. Thus, it was our conclusion that the absence of changes in the unit- and multi-directional blood chemistries supports the safety of the Plans.

Discussion
==========

This CER study was designed to compare the safety and efficacy of three bone health Plans using three independent sequentially enrolled groups of healthy women 40 years of age and older. The primary outcome measure was changes in baseline BMD (Bone Mineral Density) among participants with above average compliance in order to examine the safety and efficacy in people complying with the bone health plans as designed. However, additional analyses were also conducted using all subjects in each of the three study cohorts. Within-group comparisons of changes in BMD from baseline and between-group comparisons with the two different expected change reference groups support the safety and efficacy of all three Plans. It is also noteworthy that all three bone health plans facilitated outright increases in BMD, a finding that stands in marked contrast to a plethora of studies suggesting that calcium and vitamin D~3~ supplementation can, at best, only slow down the age-related decline in BMD.

Notwithstanding the evidence presented in this study, one could conclude that the increased MAPC from baseline and over-expected was attributable to using a sequential design with subject groups with unequal baseline demographic characteristics. The absence of a placebo-controlled arm raises concerns about placebo effects. Questions may also be raised about the validity of the two expected change reference groups to which changes in BMD in the three Plans were compared. Furthermore, the reported increase, instead of slowing, of BMD attributable to the three bone health plans stands in marked contrast to previous research and warrants further comment.

With regard to the equivalence of the groups, while it is impossible to rule out all potentially confounding variables, increased confidence in the similarity of the three groups was obtained from a comparison of baseline demographic measures of the groups that found, in general, no statistical differences between the groups in BMDs or in variables affecting BMD (weight, gender, lean mass, % fat, and BMI), in any of the 43 baseline blood chemistries, or in the QOL analyses. In all three groups, there were no differences in baseline demographics between volunteers and non-volunteers, or between those subjects who completed versus those who dropped out. Taken together, these similarities provide considerable evidence that the three groups were reasonably equivalent.

With regard to placebo effects, it seems implausible to suggest that the reported positive changes in BMD were the result of placebo effects, when the placebo groups in almost all pharmaceutical and nutritional interventions lost BMD. For example, three randomized double-blinded placebo-controlled studies measuring the effects of strontium ranelate [@B65]-[@B67] found a progressive and linear decrease in BMD in placebo groups for each of the three study years\--a 1% annual decline which was virtually identical to the age-gender adjusted expected changes used in this study. In contrast to the absence of studies on placebo effects on BMD, a number of studies have suggested that consumption of the multiple nutrients in the AC formulas could facilitate increases in BMD [@B68]. Considerable evidence is available on the bone-health effects of the nutrients in the AlgaeCal formula\--supplemental magnesium, vitamin K-2, calcium and Vitamin D~3~ [@B69]-[@B70]. Vitamin C has also been reported as an essential nutrient for collagen formation and normal bone development, particularly in older men and women [@B71]-[@B72].

With regard to the validity of the two expected change reference groups, in the non-intervention group, the estimate for an annual -0.75% decline in BMD appears conservative. The women in this study had an average age of 57.4 (41-89) which is consistent with the age-related decline of 1% to 2% cited above for women of menopausal age as well as with the data reported in the meta-analysis. As for the estimate for expected changes in BMD from traditional calcium supplementation found in the literature review, the annual decline of 0.10% is also conservative based on the studies we reviewed as well as the studies reviewed in the meta-analysis cited above.

As for the unusual finding of the increased BMD levels found in the three study groups, the superiority of Plan 3 over Plan 1 suggests that the physical activity and health literacy components may have made contributions beyond the effects of supplementation alone. As for BMD increases in Plan 1, without these components, and without definitive data, some of the explanation may be attributed to what appears to be optimal levels of vitamin D~3~ (1,000 IU) and calcium (750 mg) that were in the Plan 1 version of AC. An additional benefit may be attributed to the use of a plant-sourced form of calcium that, as discussed above, appears to be more bio-available than more traditional forms of calcium. Additionally, there are studies [@B68],[@B73]-[@B78] supporting the suggestion that plant-sourced minerals may be more easily absorbed than non-plant-sourced calcium and minerals, and that the body is able to use less than 10 percent of the minerals contained in the most popular brands of multivitamins, as opposed to over 80 percent of minerals derived from plant sources. Other studies have also reported positive associations between fruit and vegetable consumption and BMD in elderly adults [@B77]-[@B79], adolescents [@B80] and children [@B81]. Another potential explanation is that, although total body BMD is highly correlated with spinal and femur measurements, the total body measurement is less affected by the more subjective judgments made with spine and femur. In contrast to total body measurements where the operator needs only to position the patient on the scanning table, but does not need to make the more subjective decisions regarding the spinal lumbar and femoral regions.

Conclusions
===========

This study found that following any of the three Plans was associated with increases in BMD as opposed to merely slowing down the decline in BMD, which had been the general conclusions from a wide range of studies on the efficacy of vitamin D and calcium supplementation. These increases occurred without adverse side effects. While the study also provides evidence of the benefit of adding the physical activity and health literacy components, the data also support the efficacy of plant-source calcium as a stand-alone product.
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AC

:   AlgaeCal

BMD

:   Total Body Bone Mineral Density

SG

:   United States Surgeon General

CER

:   Comparative Effective Research

DXA

:   Total Body Dual-energy X-ray Absorptiometry

MAPC

:   Mean Annualized Percent Change in BMD

S\'s

:   subjects

Plan (or The Plan)

:   the plan under study, incorporating components to promote health, literacy, increased physical activity, and improved nutrition

PP

:   per protocol

QOL

:   a 50-item Quality of Life questionnaire.
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Components/ingredients in the three bone-health plans
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Quality of Life Inventory
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Listing of Blood Chemistries
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###### 

Means and between-group t-tests of baseline demographic measures for subjects following one of the three bone-health plans.
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###### 

Means and between-group t-tests of baseline demographic measures for compliant sub-groups in each of the three Plans.
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